WhiteHawk Therapeutics凭借Hwk-007的IND许可进入临床阶段,并宣布提交Hwk-016的IND申请

美股速递
Jan 08

生物制药公司WhiteHawk Therapeutics迎来重要里程碑,其候选药物Hwk-007已获得新药临床试验(IND)许可,标志着公司正式迈入临床开发阶段。与此同时,WhiteHawk Therapeutics还宣布已提交另一款候选药物Hwk-016的IND申请,进一步拓展其研发管线。

这一进展凸显了公司在创新疗法开发上的持续动力,也为后续的临床研究奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10